Facebook
Linkedin
Twitter
Industries
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Quick Byte
Resources
Search
Monday, December 29, 2025
Facebook
Linkedin
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
ReadMagazine
Industries
All
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Read Magazine’s Weekly Roundup: Discover the Most Recent News Rocket Lab,…
Prometheus Group Expands Commitment to Environmental Health and Safety with NiSoft…
TIER IV forms capital and business alliance with JR Central to…
HARMAN International Acquires ZF Group’s ADAS Unit
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Quick Byte
Resources
Home
Tags
Novel Antiepileptic Drug
Novel Antiepileptic Drug
Biotechnology
Zhimeng Biopharma Announces Dosing of First Subject of Its Novel Antiepileptic Drug Candidate CB03 in First-in-Human Phase I Clinical Trial
PR Newswire
-
May 13, 2022
Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), announced dosing of the first participant in the US Phase I study in healthy subjects of its innovative small-molecule...
0
Fans
Like
3,912
Followers
Follow
0
Subscribers
Subscribe
Hot Topics
Read Magazine’s Weekly Roundup: Discover the Most Recent News Rocket Lab, ZF Group, Vista Equity Partners, Collins Aerospace, Vuzix and More !
Prometheus Group Expands Commitment to Environmental Health and Safety with NiSoft Acquisition
TIER IV forms capital and business alliance with JR Central to support rail and autonomous driving integration
Load more
